tradingkey.logo

Actuate Therapeutics Highlights Survival Benefit In Metastatic Pancreatic Cancer Patient Populations

ReutersJun 24, 2025 1:17 PM

- Actuate Therapeutics Inc ACTU.O:

  • ACTUATE THERAPEUTICS HIGHLIGHTS SIGNIFICANT AND SUSTAINED SURVIVAL BENEFIT IN KEY METASTATIC PANCREATIC CANCER PATIENT POPULATIONS IN PHASE 2 ELRAGLUSIB TRIAL

  • ACTUATE THERAPEUTICS INC - ELRAGLUSIB PLUS GNP SHOWS NEAR DOUBLING OF 1-YEAR OS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI